Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kite Pharma, Inc. (KITE) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kite Pharma, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1510580.
Total stock buying since 2014: $5,803,660.
Total stock sales since 2014: $197,656,377.
Total stock option exercises since 2014: $15,164,987.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2017 | 81,682 | $5,667,660 | 875,902 | $81,791,822 | 502,849 | $10,948,384 |
| 2016 | 0 | $0 | 284,535 | $15,236,056 | 256,935 | $2,457,648 |
| 2015 | 0 | $0 | 1,630,944 | $100,628,499 | 457,678 | $1,758,955 |
| 2014 | 8,000 | $136,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-01-15 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 55.41 | 498,716 |
| 2016-01-15 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2016-01-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 6,800 | 54.78 | 372,531 |
| 2016-01-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 6,800 | 1.35 | 9,180 |
| 2016-01-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 55.34 | 340,082 |
| 2016-01-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2016-01-04 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 61.73 | 555,570 |
| 2016-01-04 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-12-28 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 61.70 | 616,950 |
| 2015-12-28 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-12-15 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 64.02 | 576,180 |
| 2015-12-15 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-12-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 64.11 | 613,369 |
| 2015-12-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-12-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 64.00 | 393,280 |
| 2015-12-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2015-12-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 77.95 | 701,514 |
| 2015-12-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-11-27 | Butitta Cynthia M (COO and CFO) | Sale | 15,000 | 86.62 | 1,299,375 |
| 2015-11-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 15,000 | 1.35 | 20,250 |
| 2015-11-16 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 78.42 | 705,744 |
| 2015-11-16 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-11-16 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 78.42 | 750,263 |
| 2015-11-16 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-11-16 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 78.26 | 480,907 |
| 2015-11-16 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2015-11-10 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 30,800 | 80.02 | 2,464,616 |
| 2015-11-10 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 30,800 | 6.89 | 212,212 |
| 2015-11-10 | Butitta Cynthia M (COO and CFO) | Sale | 5,000 | 80.00 | 400,000 |
| 2015-11-10 | Butitta Cynthia M (COO and CFO) | Option Ex | 5,000 | 1.35 | 6,750 |
| 2015-11-02 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,700 | 70.11 | 539,870 |
| 2015-11-02 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,700 | 6.89 | 53,053 |
| 2015-11-02 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 70.59 | 635,310 |
| 2015-11-02 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-10-27 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 70.26 | 702,570 |
| 2015-10-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-10-15 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 62.45 | 562,068 |
| 2015-10-15 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-10-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 62.34 | 596,425 |
| 2015-10-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-10-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 62.47 | 383,865 |
| 2015-10-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2015-10-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,700 | 55.11 | 424,347 |
| 2015-10-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,700 | 6.89 | 53,053 |
| 2015-10-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 55.38 | 498,384 |
| 2015-10-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-09-28 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 55.78 | 557,800 |
| 2015-09-28 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-09-15 | Wiezorek Jeffrey (VP Clinical Development) | Sale | 9,000 | 64.34 | 579,060 |
| 2015-09-15 | Wiezorek Jeffrey (VP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-09-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 64.64 | 618,382 |
| 2015-09-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-09-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 64.32 | 395,246 |
| 2015-09-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2015-09-08 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,384 | 55.00 | 406,120 |
| 2015-09-08 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,384 | 6.89 | 50,875 |
| 2015-09-03 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 316 | 55.00 | 17,380 |
| 2015-09-03 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 316 | 6.89 | 2,177 |
| 2015-09-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 52.20 | 469,800 |
| 2015-09-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-08-27 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 53.60 | 536,000 |
| 2015-08-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-08-17 | Wiezorek Jeffrey (VP Clinical Development) | Sale | 9,000 | 61.08 | 549,747 |
| 2015-08-17 | Wiezorek Jeffrey (VP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-08-17 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 60.98 | 583,366 |
| 2015-08-17 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-08-17 | Roberts Margo R (Chief Scientific Officer) | Sale | 6,145 | 60.93 | 374,414 |
| 2015-08-17 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 6,145 | 8.85 | 54,383 |
| 2015-08-03 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,700 | 72.56 | 558,712 |
| 2015-08-03 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,700 | 6.89 | 53,053 |
| 2015-08-03 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 72.64 | 653,760 |
| 2015-08-03 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-07-27 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 68.55 | 685,450 |
| 2015-07-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-07-15 | Wiezorek Jeffrey (VP Clinical Development) | Sale | 9,000 | 71.73 | 645,588 |
| 2015-07-15 | Wiezorek Jeffrey (VP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-07-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 71.90 | 687,867 |
| 2015-07-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-07-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 22,167 | 71.66 | 1,588,442 |
| 2015-07-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 22,167 | 8.85 | 196,177 |
| 2015-07-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,700 | 62.14 | 478,501 |
| 2015-07-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,700 | 6.89 | 53,053 |
| 2015-07-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 61.97 | 557,757 |
| 2015-07-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-06-30 | Champsi Farah (Director) | Sale | 664,102 | 62.55 | 41,538,251 |
| 2015-06-29 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 59.88 | 598,770 |
| 2015-06-29 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-06-15 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,700 | 56.97 | 438,645 |
| 2015-06-15 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 7,700 | 6.89 | 53,053 |
| 2015-06-15 | Wiezorek Jeffrey (VP Clinical Development) | Sale | 9,000 | 56.95 | 512,550 |
| 2015-06-15 | Wiezorek Jeffrey (VP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-06-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 56.93 | 544,678 |
| 2015-06-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-06-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 8,625 | 56.97 | 491,392 |
| 2015-06-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 8,625 | .70 | 6,037 |
| 2015-06-02 | Nussbaum Ran (Director) | Sale | 224,674 | 55.67 | 12,508,724 |
| 2015-06-01 | Nussbaum Ran (Director) | Sale | 80,760 | 56.29 | 4,545,980 |
| 2015-06-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 55.48 | 499,292 |
| 2015-06-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-05-27 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 50.95 | 509,510 |
| 2015-05-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2015-05-15 | Wiezorek Jeffrey (VP Clinical Development) | Sale | 9,000 | 50.93 | 458,352 |
| 2015-05-15 | Wiezorek Jeffrey (VP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2015-05-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 50.95 | 487,438 |
| 2015-05-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2015-05-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 8,625 | 50.92 | 439,185 |
| 2015-05-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 8,625 | .70 | 6,037 |
| 2015-05-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 51.02 | 459,207 |
| 2015-05-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2015-04-27 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 59.76 | 597,620 |
| 2015-03-30 | Nussbaum Ran (Director) | Sale | 115,857 | 59.91 | 6,941,456 |
| 2015-03-27 | Nussbaum Ran (Director) | Sale | 77,873 | 61.24 | 4,769,020 |
| 2014-06-25 | Chang David D (EVP, R&D, Chief Medical Off.) | Buy | 4,000 | 17.00 | 68,000 |
| 2014-06-25 | Wiezorek Jeffrey (VP Clinical Development) | Buy | 4,000 | 17.00 | 68,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of KITE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kite Pharma, Inc. (symbol KITE, CIK number 1510580) see the Securities and Exchange Commission (SEC) website.